 |
|
|
| |
SVR Reduces Morbidity/Deaths by 5-10 Fold - Abbvie Analysis - Percent of
Subjects Experiencing Liver Morbidity Over a Lifetime Horizon with
AbbVie 3D (Abt-450/Ritonavir/Ombitasvirand Dasabuvir) Versus No treatment
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
SJ Johnson1, H Parise1, S Virabhak1, tR Juday2, JC Samp2, SE Marx2, S Saab3
1Medicus Economics, Milton; 2Global Health Economics and Outcomes Research, AbbVie, Mettawa; 3Pfleger Liver Institute, Los Angeles, United States
EASL: The Value of Survival Benefits from Treating Hepatitis C at Different Fibrosis Stages with All-Oral, Interferon-Free Therapy Relative to 'Watchful Waiting' - (04/28/15)
EASL: Reduction in Annual Medical Costs with Early Treatment of HCV Using Abbvie 3D (AbT-450/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin in the United States - (04/28/15)
EASL: Healthcare Costs by Stage of Liver Disease in Chronic Hepatitis C Patients in the United States - (04/27/15)
|
| |
|
|
|
|
|
